Heidelberg Pharma AG, a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), will present new data from its Phase I/IIa clinical study with lead Amanitin-based ADC candidate, pamlectabart tismanitin (HDP-101), at the 23rd International Myeloma Society (IMS) Annual Meeting, being held in Glasgow, Scotland, on 23 to 26 September 2026.
Pamlectabart tismanitin is an Anti-BCMA antibody-Amanitin drug conjugate for the treatment
of relapsed or refractory multiple myeloma (RRMM), a bone marrow cancer with a high unmet
medical need. Phase I of the trial was a dose escalation study to determine an optimal and
safe dose level of the candidate for the Phase IIa part of the study.